DXCM DEADLINE ALERT: Rosen Law Firm Encourages DexCom Investors to Act Before December 29 Deadline

Global‑investor rights firm Rosen Law Firm is urging anyone who bought shares of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025 to consider joining a pending securities class action — and to secure legal counsel before the December 29, 2025 lead‑plaintiff deadline. If you qualify, you might be entitled to compensation under a contingency‑fee arrangement, meaning you pay nothing up front. The lawsuit alleges that during the “Class Period,” DexCom misled investors by failing to disclose that design changes to its G6 and G7 continuous glucose monitoring (CGM) systems — changes made without authorization from the U.S. Food and Drug Administration (FDA) — compromised their reliability and posed significant health risks to users. As a result, when the truth came out, DexCom faced heightened regulatory scrutiny and potential legal, reputational, and financial harm — and investors allegedly suffered the consequences. To join the case or request more information, you can submit the form at Rosen’s website, call toll‑free at 866‑767‑3653, or email . #DexCom #SecuritiesClassAction #InvestorAlert #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM